(Q53385153)

13 May 2018

title

Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. (English)

1 reference

13 May 2018

0 references

1 reference

10

1 reference

13 May 2018

Jens Wiltfang

11

1 reference

13 May 2018

Piotr Lewczuk

3

object named as

Lewczuk P

1 reference

13 May 2018

author name string

Bibl M

1

1 reference

13 May 2018

Mollenhauer B

2

1 reference

13 May 2018

Esselmann H

4

1 reference

13 May 2018

Wolf S

5

1 reference

13 May 2018

Trenkwalder C

6

1 reference

13 May 2018

Otto M

7

1 reference

13 May 2018

Stiens G

8

1 reference

13 May 2018

Rüther E

9

1 reference

13 May 2018

language of work or name

English

0 references

publication date

6 March 2007

1 reference

13 May 2018

published in

Molecular Psychiatry

1 reference

13 May 2018

volume

12

1 reference

13 May 2018

issue

7

1 reference

13 May 2018

page(s)

671-680

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.mp.4001967

exact match

0 references

cites work

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Amyloid beta-peptide and its relationship with dementia in Lewy body disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Abnormal tau-containing filaments in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Selective reduction of amyloid beta42 discriminates Alzheimer's disease from Huntington's disease: indication for distinct pathological events in amyloid beta peptide aggregation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

New criteria for the diagnosis of vascular dementia: do we know enough yet?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Clinical guidelines for idiopathic normal pressure hydrocephalus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Both total and phosphorylated tau are increased in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Picking away at frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Amyloid Abeta40 CSF concentrations correlate to frontal lobe atrophy in frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Conformational changes of the amyloid beta-peptide (1-40) adsorbed on solid surfaces.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Dissecting the assembly of Abeta16-22 amyloid peptides into antiparallel beta sheets.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Amyloid &#946;-Peptide [1-42]-Associated Free Radical-Induced Oxidative Stress And Neurodegeneration in Alzheimers Disease Brain: Mechanisms and Consequences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001967

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001967

1 reference

13 May 2018

PubMed ID

17339876

1 reference

13 May 2018